The Aspergillus Antigen ELISA (EUROIMMUN) provides in vitro determination of Aspergillus spp. to support the diagnosis of invasive aspergillosis (IA), a life-threatening infection in immunocompromised patients. The ELISA is especially suited for screening high-risk patients. The CE-marked assay is based on a monoclonal antibody for the detection of the Aspergillus-specific galactomannoprotein, which is produced during active fungal growth. The analysis is performed on patient serum or bronchoalveolar lavage fluid. Results can be evaluated either quantitatively in pg/ml using a 6-point calibration curve or semiquantitatively by means of a cut-off ratio. Semiautomated processing is available, for example using the EUROIMMUN Analyzer I. In a recently published clinical study with sera from patients with proven IA as well as control sera, the EUROIMMUN Aspergillus Antigen ELISA yielded comparable sensitivity and specificity to another commercially available Aspergillus antigen test (Dichtl et al, J Cli Microbiol 2019). Aspergillus spp. is a ubiquitous sac fungus, which is found in soil or compost or on damp walls. Inhalation of the spores can lead to severe disseminated infections with a high mortality in individuals with a weakened immune system. In particular, infections affecting the nervous system are nearly always fatal. High-risk groups requiring regular monitoring include patients with neutropenia, leukemia or advanced AIDS, as well as bone-marrow or organ transplant recipients. Early diagnosis and prompt treatment of IA are crucial for survival. Since clinical and radiological signs of IA are often non-specific, additional diagnostic tests such as antigen detection and culture are nearly always required to substantiate diagnosis.
Thermo Fisher Scientific has introduced several new products that build on its leading Orbitrap platform and expand research applications. The new Thermo Scientific Orbitrap Exploris 240 mass spectrometer is designed to give scientists working in proteomics, metabolomics, biopharmaceutical characterisation and small-molecules, the analytical performance required for research and high-throughput analyses. The company says the new system will advance discovery and identification with increased accuracy for confident scale-up, while providing operational simplicity and streamlining time-to-result.
Thermo Fisher Scientific pointed out that the new mass spectrometer delivers qualitative and quantitative capabilities synonymous with Orbitrap high-resolution accurate-mass (HRAM) spectrometry, with internal calibration that assures consistent data quality and decision making. These newest systems extend the Thermo Scientific Orbitrap Exploris portfolio of HRAM systems, which were introduced in 2019 with the release of the new-generation Thermo Scientific Orbitrap Exploris 480 mass spectrometer.
Thermo Scientific Proteome Discoverer 2.5 software provides high confidence during peptide identification, accurate quantification and high throughput data analysis for proteomics researchers. Deep learning-based prediction of tandem mass spectra, facilitated through a new collaboration with MSAID, a software company transforming proteomics through deep learning, enables more scientists to benefit from major improvements in identification confidence and reproducibility.
To further enhance characterisation of protein biotherapeutics and oligonucleotide therapeutics, biopharmaceutical laboratories use the Thermo Scientific BioPharma Finder 4.0 software, which provides greater flexibility and customisation for this growing industry.
For small molecule researchers, Thermo Scientific Compound Discoverer 3.2 software further automates unknown compound identification performed on Thermo Scientific Orbitrap Gas Chromatography- Mass Spectrometry (GC-MS) systems to improve productivity.
In addition, the new Thermo Scientific Xcalibur 4.4 software brings the AcquireX intelligent data acquisition workflow to Thermo Scientific Orbitrap Exploris mass spectrometry platform users, enabling the fully automated acquisition of high quality MS/MS data and reducing manual input and repeat runs.
Thermo Fisher Scientific’s collaboration with Evosep, a leading provider of sample preparation technologies for protein-based clinical research, supports the development of high-throughput clinical research workflows for profiling large plasma sample cohorts for proteomics, translational research and pharmaceutical applications. This partnership recently led to the launch of an automated ultra-high throughput plasma protein profiling platform, combing the power of the new Thermo Scientific Orbitrap Exploris 240 mass spectrometer with the Evosep One liquid chromatography solution.
The company’s collaboration with Biognosys, a leading developer of next-generation proteomics solutions, resulted in the development of data-independent acquisition mass spectrometrybased workflows, which enhances sensitivity and coverage for proteomic research in translational and clinical labs. The collaboration includes a novel FAIMS-DIA method that features the Thermo Scientific FAIMS Pro interface, which improves selectivity, reproducibility and proteome coverage, as well as new methods that streamline discovery by combining Thermo Scientific SureQuant Targeted Assay Kits and the Biognosys PQ500 kit in a single workflow.
For more information, visit: www.thermofisher.com
AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA). A new cfPureMax kit is now available for use on samples of 5 ml volume or greater.
AMSBIO cfPure kits use silica-coated paramagnetic particles to purify cell free DNA from less than 1 ml to greater than 10 ml of serum or plasma. The buffers were developed to ensure efficient recovery of 100-500 bp DNA fragments in order to maximize recovery of cell free DNA. The recovered DNA is suitable for a wide range of down-stream applications, such as bisulfite sequencing, NGS, and qPCR.
The cfPure protocol is rapid and easy, allowing users to process several samples in an hour or less and making it ideal for biomarker screening. Using proprietary silica-coated magnetic bead technology, cfPure kits are able to efficiently recover low molecular weight cell free DNA during isolation – a key success factor for successful analysis of cfDNA. Designed for scalability, cfPure kits enable you to use just the number of beads and amount of reagent that you need for your cfDNA extraction. This also means that the number of extractions per kit is dependent on the amount of sample you wish to purify DNA from.
In addition to being easy to perform, scalable and easy to automate, cfPure kits allow you to use less magnetic bead solution if you are purifying small amounts of plasma – saving you money.
Since cfDNA is typically found at very low concentrations and in a fragmented state, very efficient DNA capture, as provided by AMSBIO’s cfPure Cell Free DNA Purification Kits, is vital to provide sensitive and reliable results.
For more information, visit www.amsbio.com/circulating-cell-free-DNA.aspx
Hemco has introduced the CleanAire II Ductless Hoods, designed to meet DH I requirements as defined by SEFA 9. This hood features a built-in carbon filtration system to adsorb non-toxic fumes and odors. It is equipped with an integral blower, vapor proof light, fan and light switches.
The hood superstructure is constructed of chemical and flame resistant, non-metallic (no rust) composite resin with a molded one-piece seamless interior fume chamber. A vertical sliding clear acrylic sash protects the user and contains the process fumes. The carbon filter adsorbs the fumes and then re-circulates the air back to the laboratory.
The CleanAire II Ductless Hoods are available in 24”, 30”, 35”, and 47” models and are shipped completely assembled and ready for operation.
For more information, visit: www.hemcocorp.com/caii.html
New CE-marked chemiluminescence immunoassays (ChLIA) for detection of antibodies against Borrelia, Epstein-Barr virus (EBV-CA, EBNA), proteinase 3 (PR3) and phospholipase A2 receptor (PLA2R) on the EUROIMMUN RA Analyzer 10 system are available now. Different immunoglobulin classes can be analysed depending on the application, with assays encompassing anti-Borrelia IgG and IgM, anti-EBV-CA IgG and IgM, anti-EBNA IgG, anti-PR3 IgG and anti-PLA2R IgG. The random access system, used in conjunction with the ChLIA products, functions as a compact automation solution in small- to medium-sized laboratories, or complements high-throughput-devices in large-sized laboratories. Test- and lot-specific information, including stored standard curves, are imported into the database by means of an RFID code, enabling error-free and convenient loading, along with efficient and secure test evaluation. The EURO-IMMUN RA Analyzer 10 allows continuous loading — also as part of a laboratory track system — to ensure that every sample is processed with minimal effort as a single determination. The ChLIA technology offers short reaction times, with total analysis in 30 minutes or less. In addition, the preferred processing of emergency samples (STAT) gives laboratories with different requirements and sample volumes flexibility in their laboratory routine.
Now available for Horiba Medical’s Yumizen G hemostasis range of instruments, the new Yumizen G DDi 2 (D-Dimer) reagent kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). HORIBA Medical’s new D-Dimer reagent kit is available for its full range of coagulation instruments which covers the needs of any laboratory. The dedicated hemostasis portfolio includes the fully automatic Yumizen G800, Yumizen G1500 and Yumizen G1550, as well as semi-automatic Yumizen G200 and Yumizen G400 analysers. Using antibody-coated latex particles and measured via the immuno-turbidimetric channels of these Yumizen G instruments, the new reagent kit delivers D-Dimer results consistency across the range. The D-Dimer assay when used on very compact coagulation screening platforms such as the Yumizen G400DDi and Yumizen G200, which also have combined immuno-turbidimetric and chromogenic assay capabilities, is particularly suitable for small laboratories, hot labs and as backup. On these semi-automatic systems, the Yumizen G DDi 2 reagent kit offers an innovative combination of immuno-turbidimetric test capability and pre-calibrated ready-to-use reagent. Offering a cost-efficient solution, the new assay minimizes preparation time due to its ready-to-use liquid format. Furthermore, as the reagent is pre-calibrated it removes the need for a costly and time-consuming calibration step. Its high stability and optimized volume packaging also avoid wastage. HORIBA Medical’s new D-Dimer test kit is fully compliant with Gold Standard performances, having a Negative Predictive Value of 99% and an absence of hook effect up to 25 µg FEU/ml. It also offers slope check and post dilution function on both fully automatic and semi-automatic systems with a cut-off value at 0.5 µg FEU/ml.
Porvair Sciences report how its Chromatrap ChIP kits provide an outstanding solution for antibodies suppliers looking to validate the performance of the antibodies they produce for chromatin immunoprecipitation (ChIP) assay kits.
With its revolutionary bead-free system, Chromatrap offers a faster, easier and more sensitive method to validate antibodies in a high throughput format. This enables antibody suppliers to easily and efficiently expand their product portfolio to target epigenetics and drug development applications.
Successful ChIP assays heavily rely on the highest quality antibodies. In-house validation of antibodies for use in ChIP is considered to be a lengthy, expensive, time consuming and challenging process. In addition, antibodies are rigorously assessed for enrichment of positive and negative gene targets, signal-to-noise ratio, chromatin-to-antibody ratio, reproducibility and lot-to-lot variations.
Dr Lindsay Parkes, a senior research scientist at Porvair Sciences commented: “We have developed our bead-free Chromatrap technology to enable maximum capture of antibody. This is achieved by correctly orientated capture proteins throughout the inert filter-based ChIP technology. Most bead-based systems have capture proteins scattered in random orientation which doesn’t allow full access of antibodies to binding pockets of proteins, thus giving an overall reduced capture efficiency. This is important for high sensitivity especially for detection of binding of low abundant targets.”
Chromatrap ChIP kits deliver fast workflow, enabling you to process up to 96 ChIP assays simultaneously in one day allowing multiple sample, antibody and gene targets to be tested in parallel on a single plate. Requiring less manual handling and fewer pipetting steps than other ChIP kits, Chromatrap ChIP kits are very easy to use, making them perfect for even inexperienced users. Using these kits, a complete ChIP protocol doesn’t require overnight incubation or blocking steps and can be completed in under five hours. Chromatrap ChIP-kits are suitable for use over a wide chromatin enrichment range (500ng – 50µg).
For further information on Chromatrap® ChIP kits for antibody validation, visit: https://www.chromatrap.com/high-throughput-chip-kits/
CE marking has been granted to one of the most comprehensive cartridge-based STI tests. The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology. Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling. Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented; “Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”
The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size. Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.
Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said: “We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”
The LC-MS/MS-based assay MassTox drugs of abuse testing offers the target screening and quantitative confirmation of more than 100 drugs and metabolites with an analysis time of up to 12 minutes. The CE-IVD validated solution includes everything that is required for the analysis, eliminating the need for developing and maintaining several in-house methods or for preparing QC materials for a multitude of analyte compounds. It is designed to work below cut-offs defined by GTFCh and EWDTS. The assay includes a carefully selected hydrolysis enzyme that ensures a complete and selective hydrolysis of all 108 drugs covered in the assay. 99 analytes are safeguarded by isotopically labelled internal standards. The high stability of the 6PLUS1 Multilevel Urine Calibrator Set and three MassCheck urine controls ensure reliable results with highest precision.